130 related articles for article (PubMed ID: 36088220)
1. Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma.
Valery M; Cervantes B; Smolenschi C; Boilève A; Boige V; Malka D; Hollebecque A; Ducreux M
Dig Liver Dis; 2023 Mar; 55(3):407-411. PubMed ID: 36088220
[TBL] [Abstract][Full Text] [Related]
2. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Raoul JL; Van Laethem JL; Peeters M; Brezault C; Husseini F; Cals L; Nippgen J; Loos AH; Rougier P
BMC Cancer; 2009 Apr; 9():112. PubMed ID: 19366444
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor inhibition in metastatic anal cancer.
Rogers JE; Ohinata A; Silva NN; Mehdizadeh A; Eng C
Anticancer Drugs; 2016 Sep; 27(8):804-8. PubMed ID: 27272412
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.
Blick SK; Scott LJ
Drugs; 2007; 67(17):2585-607. PubMed ID: 18034592
[TBL] [Abstract][Full Text] [Related]
8. Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.
Chen Y; Cao D; Bi F; Li Q; Qiu M
Med Oncol; 2014 May; 31(5):935. PubMed ID: 24683007
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Folprecht G; Lutz MP; Schöffski P; Seufferlein T; Nolting A; Pollert P; Köhne CH
Ann Oncol; 2006 Mar; 17(3):450-6. PubMed ID: 16303861
[TBL] [Abstract][Full Text] [Related]
10. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Stouvenot M; Meurisse A; Saint A; Buecher B; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Smith D; Ghiringhelli F; Parzy A; de la Fouchardiere C; Almotlak H; Vienot A; Jacquin M; Taieb J; Nguyen T; Vernerey D; Borg C; Kim S
Eur J Cancer; 2022 Feb; 162():138-147. PubMed ID: 34995900
[TBL] [Abstract][Full Text] [Related]
11. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.
Kim DW; Byer J; Kothari N; Mahipal A; Chang YD; Kim RD
Oncology; 2017; 92(4):190-196. PubMed ID: 28152526
[TBL] [Abstract][Full Text] [Related]
12. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
13. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.
Phan LK; Hoff PM
Dis Colon Rectum; 2007 Mar; 50(3):395-8. PubMed ID: 17252287
[TBL] [Abstract][Full Text] [Related]
14. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Moosmann N; Heinemann V
Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
[TBL] [Abstract][Full Text] [Related]
16. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
17. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Khawandanah M; Baxley A; Pant S
J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
20. [Effects of radical radiotherapy combined with different regimens of chemotherapy on radiation intestinal injury in patients with non-metastatic anal squamous cell carcinoma].
Pang XL; Liu S; Liu YP; Chen HY; He F; Zheng J; Wan XB
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):977-983. PubMed ID: 34823298
[No Abstract] [Full Text] [Related]
[Next] [New Search]
